health

Imagine a world where your local membership shopping club or health/fitness club could sell health insurance to members

For mostly political reasons, hydroxychloroquine has become a highly controversial drug

As of now, every bit of COVID-19 good news is being buried or tainted with doubts.

The American Medical Association and many other professional organizations demand “peer-reviewed science” before they will recommend or even accept the re-purposing of a long-established anti-malaria drug to treat or prevent COVID-19.

Due to coronavirus, governments across the globe are considering and/or are doing something they certainly could not do before: implement mass surveillance programs to track COVID-19 patients.

We have yet to record meaningful samples of the general population with regard to the prevalence of coronavirus, the distribution of its outcomes, and the build-up of immunity.

If the COVID-19 crisis has taught us one thing—aside from the need to wash your hands often—it is that the FDA’s approval process for much-needed medicine to those with debilitating and terminal diseases is in dire need of reform.

Fear of litigation delayed delivery of millions of N95 masks for healthcare workers. Should the law be slowing our emergency response?

Junk science and scare stories stampede countries into taking drastic, unnecessary action.

The word has leaked out on a potential cheap treatment for COVID-19, the antimalarial drug hydroxychloroquine.

Our lives and economy have been disrupted on an unprecedented scale by COVID-19. How do we calculate the societal impact?

In their frantic attempts to delay the spread of the Wuhan virus, governments are sowing the seeds of economic depression and currency destruction.

Social distancing is the prescribed solution to the COVID-19 pandemic. Did we ever consider the other options?